EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Zentalis Pharmaceuticals Llc (ZNTL) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Zentalis Pharmaceuticals Llc $2.53, price $2.87, upside -11.9%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US98943L1070

ZP Zentalis Pharmaceuticals Llc logo Thin data Sep 23, 2026

Zentalis Pharmaceuticals Llc

ZNTL · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $2.53 · Overvalued (−12%)
!Quality 38/100
!Weak Growth
!negative free cash flow
!Mixed vs. peers (4/8)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 18 out of 100
Watch Zentalis Pharmaceuticals Llc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$84.79 $1.04 Fair Value $2.53 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $1.04 – $84.79 · fair‑value band $1.67 – $3.17 · the $2.87 price screens above the $2.53 fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow Zentalis Pharmaceuticals Llc in your weekly email

Every Wednesday you see whether Zentalis Pharmaceuticals Llc is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.

Show more

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

Stock analysis

Zentalis Pharmaceuticals Llc (ZNTL) currently trades at $2.87, while our model-based Fair Value estimate is $2.53, implying the stock looks roughly 13.4% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $1.67 (bear) to $3.17 (bull), the price of $2.87 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Zentalis Pharmaceuticals Llc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$137M in FY2025.

Key figures

Market cap $283M · P/S ratio 10.5 · EPS (TTM) $−1.74 · Return on equity −51.9% · Return on assets (EBIT) −47.5% · Revenue (TTM) $26.9M · Free cash flow −$125M · Net debt $3.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 124% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −12%, ZNTL screens richer than that median.

Fair Value models

Bear $1.67 Fair Value $2.53 Bull $3.17
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $1.52 $2.03 $3.04 51
All 1 models by family
Asset-Based
NCAV (Graham) $1.52 $2.03 $3.04 51

Open the full fair value analysis →

Notify me when ZNTL reaches fair value

Put ZNTL on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 38/100

Of which business quality 41 · Market factors (momentum, volatility) 42

Profitability 0
Margins and returns on capital today
Quality Growth 0
Are margins and returns improving?
Cashflow 64
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 58
Price trend over the last 3–12 months (market factor)
52W Momentum 65
Distance to the 52-week high (market factor)
Net Issuance 35
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ZNTL screens 13% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Zentalis Pharmaceuticals Llc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Below median
Fair Value upside −12% · Above median
Profitability
Return on assets −28% · Below median
Operating margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.31× · Cheaper than median
P/S (TTM) 10.52× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)18 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zentalis Pharmaceuticals Llc · Fair Value
$2.53 −13%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Zentalis Pharmaceuticals Llc Fair Value". https://www.fairvalue-calculator.com/stock/ZNTL

Frequently asked questions

Is Zentalis Pharmaceuticals Llc (ZNTL) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $2.53 versus a price of $2.87, about −12% upside (overvalued).
What is the fair value of ZNTL?
Our model-based fair value for Zentalis Pharmaceuticals Llc is $2.53 (as of Sep 23, 2026), built from audited fundamentals. The current price: $2.87.
What is the quality score of ZNTL?
Zentalis Pharmaceuticals Llc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zentalis Pharmaceuticals Llc (ZNTL)?
Our model-based price target is the fair value of $2.53 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $1.67, optimistic scenario $3.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Zentalis Pharmaceuticals Llc stock forecast for 2026?
Our models put fair value at $2.53, about −12% upside versus a price of $2.87 (overvalued). Cautious scenario $1.67, optimistic scenario $3.17. The calculation is refreshed regularly with new filings.
What is the revenue of Zentalis Pharmaceuticals Llc (ZNTL)?
Zentalis Pharmaceuticals Llc reported trailing-twelve-month revenue of about $26.9M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Zentalis Pharmaceuticals Llc (ZNTL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zentalis Pharmaceuticals Llc it is $2.53 per share (as of Sep 23, 2026), against a price of $2.87. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Zentalis Pharmaceuticals Llc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ZNTL trades above its calculated fair value: price $2.87, fair value $2.53, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZNTL?
No. The price is what the market pays today ($2.87); the fair value is what the company's own numbers justify ($2.53). For Zentalis Pharmaceuticals Llc the two are $0.3400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zentalis Pharmaceuticals Llc worth?
The market values Zentalis Pharmaceuticals Llc at about $283M (market capitalisation, as of Sep 23, 2026). Per share that is $2.87; our models calculate a fair value of $2.53 per share.
What do the bullish and bearish scenarios say about ZNTL?
Our models span a range for Zentalis Pharmaceuticals Llc: cautious scenario $1.67, base $2.53, optimistic $3.17 per share (as of Sep 23, 2026, price $2.87). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zentalis Pharmaceuticals Llc (ZNTL)?
Balance-sheet figures for Zentalis Pharmaceuticals Llc (as of Sep 23, 2026): return on equity −51.9%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is ZNTL from its 52-week high?
Zentalis Pharmaceuticals Llc trades at $2.87, about 57% below its 52-week high of $6.61 and 124% above the low of $1.28 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $2.53 is for.
Which stocks are comparable to Zentalis Pharmaceuticals Llc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zentalis Pharmaceuticals Llc stock attractive at the current price?
The data as of Sep 23, 2026: price $2.87, calculated fair value $2.53 (−12%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZNTL calculated?
We run Zentalis Pharmaceuticals Llc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.53, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Zentalis Pharmaceuticals Llc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zentalis Pharmaceuticals Llc (ZNTL)?
The closing price on Sep 23, 2026 was $2.87. Our model-based fair value is $2.53, about −12% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zentalis Pharmaceuticals Llc right now?
A fairly wide model range ($1.67 to $3.17) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Zentalis Pharmaceuticals Llc

How large is the market capitalisation of Zentalis Pharmaceuticals Llc (ZNTL)?
The market capitalisation of Zentalis Pharmaceuticals Llc is $283M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zentalis Pharmaceuticals Llc (ZNTL)?
The price-to-sales ratio of Zentalis Pharmaceuticals Llc is 10.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zentalis Pharmaceuticals Llc (ZNTL)?
Earnings per share at Zentalis Pharmaceuticals Llc are $−1.74. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Zentalis Pharmaceuticals Llc (ZNTL)?
The return on equity (ROE) of Zentalis Pharmaceuticals Llc is −51.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zentalis Pharmaceuticals Llc (ZNTL)?
On an EBIT basis the return on assets of Zentalis Pharmaceuticals Llc is −47.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Zentalis Pharmaceuticals Llc (ZNTL) generate?
The free cash flow of Zentalis Pharmaceuticals Llc is −$125M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zentalis Pharmaceuticals Llc (ZNTL) carry?
The net debt of Zentalis Pharmaceuticals Llc is $3.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Zentalis Pharmaceuticals Llc in the live analysis

One click puts Zentalis Pharmaceuticals Llc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.